In contrast to these findings, however, a recent study administered a PERK inhibitor to P301L tau transgenic mice suggesting that PERK inhibition may be a viable treatment strategy for tauopathies (Radford et al, 2015). The gene discussed is MAPT; the disease is tauopathy.